CA2132091A1 - Antibodies to alphavbeta3 integrin - Google Patents

Antibodies to alphavbeta3 integrin

Info

Publication number
CA2132091A1
CA2132091A1 CA002132091A CA2132091A CA2132091A1 CA 2132091 A1 CA2132091 A1 CA 2132091A1 CA 002132091 A CA002132091 A CA 002132091A CA 2132091 A CA2132091 A CA 2132091A CA 2132091 A1 CA2132091 A1 CA 2132091A1
Authority
CA
Canada
Prior art keywords
beta
monoclonal antibodies
bone resorption
integrin
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002132091A
Other languages
French (fr)
Other versions
CA2132091C (en
Inventor
Kyung J. Kim
Michael A. Horton
Sarah C. Bodary
Anan Chuntharapai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Kyung J. Kim
Michael A. Horton
Sarah C. Bodary
Anan Chuntharapai
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyung J. Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai, Genentech, Inc. filed Critical Kyung J. Kim
Publication of CA2132091A1 publication Critical patent/CA2132091A1/en
Application granted granted Critical
Publication of CA2132091C publication Critical patent/CA2132091C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Abstract

The invention relates to monoclonal antibodies to the av.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption.
The disclosed monoclonal antibodies are believed to recognize unique epitopes on av.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
CA002132091A 1992-04-03 1993-03-30 Antibodies to alphavbeta3 integrin Expired - Lifetime CA2132091C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86267992A 1992-04-03 1992-04-03
US07/862,679 1992-04-03
US2591393A 1993-03-03 1993-03-03
US08/025,913 1993-03-03
PCT/US1993/002987 WO1993020229A1 (en) 1992-04-03 1993-03-30 ANTIBODIES TO ALPHAvBETA3 INTEGRIN

Publications (2)

Publication Number Publication Date
CA2132091A1 true CA2132091A1 (en) 1993-10-14
CA2132091C CA2132091C (en) 2008-09-16

Family

ID=26700459

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002132091A Expired - Lifetime CA2132091C (en) 1992-04-03 1993-03-30 Antibodies to alphavbeta3 integrin

Country Status (8)

Country Link
US (5) US5578704A (en)
EP (1) EP0633945B1 (en)
JP (1) JP3353209B2 (en)
AT (1) ATE175241T1 (en)
AU (1) AU680411B2 (en)
CA (1) CA2132091C (en)
DE (1) DE69322860T2 (en)
WO (1) WO1993020229A1 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
US7132260B2 (en) * 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
WO1992017602A1 (en) * 1991-04-05 1992-10-15 The General Hospital Corporation Office Of Technology Affairs Parathyroid hormone receptor and dna encoding same
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
SG52262A1 (en) * 1993-01-08 1998-09-28 Tanabe Seiyaku Co Peptide inhibitors of cell adhesion
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
ATE244306T1 (en) * 1994-12-20 2003-07-15 Merck Patent Gmbh MONOCLONAL ANTIBODY AGAINST THE ALPHA-V INTEGRIN
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
RU2195312C2 (en) 1996-05-31 2002-12-27 Дзе Скриппс Рисерч Инститьют TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αvβ5-CAUSED ANGIOGENESIS
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (en) * 1996-12-09 2009-06-15 Merck Patent Gmbh ADHESION RECEIVER ALFAVBET3 RECOMBINANT SOLUBLE.
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
DE69828154T2 (en) 1997-03-12 2005-06-23 Smithkline Beecham Corp. ANTI-ALPHAVBETA3 HUMANIZED MONOCLONAL ANTIBODIES
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6193968B1 (en) 1997-04-11 2001-02-27 The Burnham Institute Methods for using anti-αvβ3 integrin antibody
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
DE19828068C2 (en) * 1998-06-24 2003-12-18 Peter Dietsch Specific inhibitor of osteoclast bone resorption
WO2000009143A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
NZ511937A (en) * 1998-12-04 2004-02-27 Novartis Ag Methods and compositions for targeting an activated vitronectin receptor with a ligand comprising adenovirus-2 penton base or fragment thereof
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7049140B1 (en) 1999-04-29 2006-05-23 Vanderbilt University X-ray guided drug delivery
US6159443A (en) * 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
DE60042700D1 (en) * 1999-09-08 2009-09-17 Markus Albers INTEGRIN-MEDICINED MEDICINAL TARGET DIRECTION
JP4307775B2 (en) * 1999-10-28 2009-08-05 ゼイェトホサイン・アハリネヤート Use of CSF-1 inhibitors
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
DK1297016T3 (en) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Use of placental growth factor inhibitors to treat pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and / or vascular leakage
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219305A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
IL157706A0 (en) * 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
JP2005525368A (en) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド Method for preventing or treating disorders in which an integrin αvβ3 antagonist is administered in combination with an HMG-CoA reductase inhibitor or bisphosphonate
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP2005535572A (en) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド Recombinant anti-interleukin-9 antibody
US20050186204A1 (en) * 2002-06-28 2005-08-25 Peter Carmeliet Use of antibodies against FLT-1 for the treatment of osteoporosis
EP1517703B1 (en) * 2002-06-28 2007-03-21 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Placental growth factor as a target for the treatment of osteoporosis
CA2514653A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
ES2391087T3 (en) * 2003-04-11 2012-11-21 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
WO2005117936A2 (en) * 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
MXPA06014069A (en) 2004-06-04 2007-04-25 Genentech Inc Method for treating multiple sclerosis.
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2601267C (en) * 2005-03-24 2014-02-18 Thromb-X N.V. Novel anti-plgf antibody
WO2007003609A1 (en) * 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US7862813B2 (en) * 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
EP3669878A1 (en) 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP5522717B2 (en) * 2008-09-19 2014-06-18 国立大学法人佐賀大学 Atopic dermatitis detection method and prophylactic / therapeutic agent screening method
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2374002A1 (en) * 2008-12-23 2011-10-12 GE Healthcare UK Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
DK3903829T3 (en) 2009-02-13 2023-06-26 Immunomedics Inc IMMUNE CONJUGATES WITH AN INTRACELLULAR CLEAVABLE BOND
IN2012DN01663A (en) 2009-09-16 2015-06-05 Immunomedics Inc
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK2785739T3 (en) 2011-12-01 2017-07-03 Thrombogenics Nv IMPROVING THE RESULT OF TREASURE CULECTOMY
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2809684A1 (en) 2012-01-31 2014-12-10 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
RU2015106333A (en) 2012-08-31 2016-10-27 Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл MONOCLONAL ANTIBODIES TO STIMULATE OR INHIBIT AN INSULIN-LIKE GROWTH FACTOR 1 (IGF-1)
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
HUE057977T2 (en) 2012-12-13 2022-06-28 Immunomedics Inc Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
PL3204018T3 (en) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
ES2953441T3 (en) 2015-06-25 2023-11-13 Immunomedics Inc Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
KR20180075537A (en) 2015-10-06 2018-07-04 제넨테크, 인크. Methods for treating multiple sclerosis
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
KR102101561B1 (en) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 Angiogenesis target constrast medium and a method for producing the same
CN113557246B (en) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 Targeting alpha v β 3 Single domain antibodies to integrins
JP2024512824A (en) 2021-01-22 2024-03-19 ロイヤル カレッジ オブ サージャンズ イン アイルランド coronavirus treatment
JPWO2022239720A1 (en) 2021-05-10 2022-11-17

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
JPH02502156A (en) * 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Monoclonal antibody against RGD-directed adhesion receptor of endothelial cells
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites

Also Published As

Publication number Publication date
WO1993020229A1 (en) 1993-10-14
AU3941393A (en) 1993-11-08
DE69322860T2 (en) 1999-07-01
JP3353209B2 (en) 2002-12-03
US5652109A (en) 1997-07-29
ATE175241T1 (en) 1999-01-15
AU680411B2 (en) 1997-07-31
CA2132091C (en) 2008-09-16
DE69322860D1 (en) 1999-02-11
US6369204B1 (en) 2002-04-09
US5652110A (en) 1997-07-29
EP0633945A1 (en) 1995-01-18
JPH07505528A (en) 1995-06-22
EP0633945B1 (en) 1998-12-30
US6359126B1 (en) 2002-03-19
US5578704A (en) 1996-11-26

Similar Documents

Publication Publication Date Title
CA2132091A1 (en) Antibodies to alphavbeta3 integrin
EP0831880A4 (en) Antibody and antibody fragments for inhibiting the growth of tumors
AU5845394A (en) Biocompatible, surface modified materials and method of making the same
EP0553860A3 (en) Semiconductor substrate and process for preparing the same
EP0553857A3 (en) Semiconductor substrate and process for preparing the same
HUP0004649A3 (en) Narrow mwd, compositionally optimized ethylene interpolymer composition, process for making the same and article made therefrom
IL114397A0 (en) Growth/differentiation factor of the TGF-beta-family
HK1009976A1 (en) Powder having at least one layer and process for preparing the same
EP0553859A3 (en) Semiconductor substrate and process for producing the same
HK1031469A1 (en) Gan single crystalline substrate and method of producing the same.
EP0594994A3 (en) Semiconductor diamond and process for producing the same.
ZA963106B (en) Scouring articles and process for the manufacture of same.
HUT63868A (en) Grain for grinding composition, grinding composition and process for producing the grain
EP0599510A3 (en) Improvements in or relating to the formation of images.
AU7839594A (en) Strategy for the production of rna from immobilized templates
AU3943793A (en) Methods of inhibiting or enhancing scar formation in the CNS
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
EP0589411A3 (en) Silicon nitride sintered body and process for producing the same.
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
HUP9903506A3 (en) Use of griseofulvin for inhibiting the growth of cancers
AU639366B2 (en) Artificial soil and process for producing the same
GR3021203T3 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane.
EP0971032A4 (en) Growth promoting material for useful microorganisms and process for producing the same
EP0569141A3 (en) Methods of inhibiting the growth of multidrug resistant tumors with an antibody.
ZA934868B (en) Amidines derived from 3-aminoethyl indoles and process for the preparation thereof

Legal Events

Date Code Title Description
EEER Examination request